Table 2. The efficacy of Cas9-mediated modifications in goat fibroblasts and tested individuals.
| Target gene | Fibroblasts | Tested individuals |
|---|---|---|
| MSTN | 15/26 (57.7%) | 15/98 (15.3%) |
| FGF5 | 11/18 (61.1%) | 21/98 (21.4%) |
| FGF5&MSTN | − | 10/98 (10.2%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.